Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
BioLife Solutions

BioLife Solutions (NASDAQ: BLFS) insider transactions

In the twelve months to 10 November 2026, executives and directors of BioLife Solutions reported 39 open-market sales of 1,452,223 shares ($34.0m) and 0 open-market purchases, by 9 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in BioLife Solutions shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
6 October 2026Werner SeanChief Technology OfficerGrant or award+45,838—47,033Form 4
6 October 2026Werner SeanChief Technology OfficerGrant or award+48,232—95,265Form 4
6 October 2026Werner SeanChief Technology OfficerShares withheld for tax−71,226$38.6124,039Form 4
6 October 2026Werner SeanChief Technology OfficerReturned to the company−69,979—0Form 4
6 October 2026Berard ToddChief Marketing OfficerGrant or award+38,198—162,567Form 4
6 October 2026Berard ToddChief Marketing OfficerGrant or award+40,192—202,759Form 4
6 October 2026Berard ToddChief Marketing OfficerShares withheld for tax−46,170$38.61156,589Form 4
6 October 2026Berard ToddChief Marketing OfficerReturned to the company−194,786—0Form 4
6 October 2026Mathew Aby J.EVP & Chief Scientific OfficerGrant or award+45,838—343,866Form 4
6 October 2026Mathew Aby J.EVP & Chief Scientific OfficerGrant or award+40,192—384,058Form 4
6 October 2026Mathew Aby J.EVP & Chief Scientific OfficerShares withheld for tax−70,000$38.61314,058Form 4
6 October 2026Mathew Aby J.EVP & Chief Scientific OfficerReturned to the company−404,608—0Form 4
6 October 2026Moore Timothy L.DirectorReturned to the company−44,943—0Form 4
6 October 2026Hunt AnthonyDirectorReturned to the company−15,046—0Form 4
6 October 2026De Greef RoderickChief Executive OfficerGrant or award+225,670—567,186Form 4
6 October 2026De Greef RoderickChief Executive OfficerGrant or award+237,460—804,646Form 4
6 October 2026De Greef RoderickChief Executive OfficerShares withheld for tax−364,872$38.61439,774Form 4
6 October 2026De Greef RoderickChief Executive OfficerReturned to the company−826,454—0Form 4
6 October 2026Coste CatherineDirectorReturned to the company−13,871—0Form 4
6 October 2026DuRoss AmyDirectorReturned to the company−26,857—0Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the BioLife Solutions page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.